Global Lung Cancer Genomic Testing Supply, Demand and Key Producers, 2023-2029
The global Lung Cancer Genomic Testing market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
This report studies the global Lung Cancer Genomic Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Lung Cancer Genomic Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Lung Cancer Genomic Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Lung Cancer Genomic Testing total market, 2018-2029, (USD Million)
Global Lung Cancer Genomic Testing total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Lung Cancer Genomic Testing total market, key domestic companies and share, (USD Million)
Global Lung Cancer Genomic Testing revenue by player and market share 2018-2023, (USD Million)
Global Lung Cancer Genomic Testing total market by Type, CAGR, 2018-2029, (USD Million)
Global Lung Cancer Genomic Testing total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Lung Cancer Genomic Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CD Genomics, Qiagen NV, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Agilent Technologies Inc., Illumina Inc., Thermo Fischer Scientific Inc., Abbott Laboratories Inc. and Quest Diagnostics Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Lung Cancer Genomic Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Lung Cancer Genomic Testing Market, By Region:
1. How big is the global Lung Cancer Genomic Testing market?
2. What is the demand of the global Lung Cancer Genomic Testing market?
3. What is the year over year growth of the global Lung Cancer Genomic Testing market?
4. What is the total value of the global Lung Cancer Genomic Testing market?
5. Who are the major players in the global Lung Cancer Genomic Testing market?
6. What are the growth factors driving the market demand?
This report studies the global Lung Cancer Genomic Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Lung Cancer Genomic Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Lung Cancer Genomic Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Lung Cancer Genomic Testing total market, 2018-2029, (USD Million)
Global Lung Cancer Genomic Testing total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Lung Cancer Genomic Testing total market, key domestic companies and share, (USD Million)
Global Lung Cancer Genomic Testing revenue by player and market share 2018-2023, (USD Million)
Global Lung Cancer Genomic Testing total market by Type, CAGR, 2018-2029, (USD Million)
Global Lung Cancer Genomic Testing total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Lung Cancer Genomic Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CD Genomics, Qiagen NV, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Agilent Technologies Inc., Illumina Inc., Thermo Fischer Scientific Inc., Abbott Laboratories Inc. and Quest Diagnostics Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Lung Cancer Genomic Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Lung Cancer Genomic Testing Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Liquid Biopsy
- Tissue Biopsy
- Hospitals/Clinics
- Research Organization
- Diagnostic Laboratories
- CD Genomics
- Qiagen NV
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories
- Agilent Technologies Inc.
- Illumina Inc.
- Thermo Fischer Scientific Inc.
- Abbott Laboratories Inc.
- Quest Diagnostics Inc.
- OncoDNA
- Centogene N.V.
- Admera Health
- CeGaT GmbH
- OPKO Health Inc.
- F. Hoffmann-La Roche AG.
1. How big is the global Lung Cancer Genomic Testing market?
2. What is the demand of the global Lung Cancer Genomic Testing market?
3. What is the year over year growth of the global Lung Cancer Genomic Testing market?
4. What is the total value of the global Lung Cancer Genomic Testing market?
5. Who are the major players in the global Lung Cancer Genomic Testing market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Lung Cancer Genomic Testing Introduction
1.2 World Lung Cancer Genomic Testing Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Lung Cancer Genomic Testing Total Market by Region (by Headquarter Location)
1.3.1 World Lung Cancer Genomic Testing Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.3 China Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.4 Europe Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.5 Japan Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.6 South Korea Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.7 ASEAN Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.8 India Lung Cancer Genomic Testing Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Lung Cancer Genomic Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Lung Cancer Genomic Testing Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.2 World Lung Cancer Genomic Testing Consumption Value by Region
2.2.1 World Lung Cancer Genomic Testing Consumption Value by Region (2018-2023)
2.2.2 World Lung Cancer Genomic Testing Consumption Value Forecast by Region (2024-2029)
2.3 United States Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.4 China Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.5 Europe Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.6 Japan Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.7 South Korea Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.8 ASEAN Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.9 India Lung Cancer Genomic Testing Consumption Value (2018-2029)
3 WORLD LUNG CANCER GENOMIC TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Lung Cancer Genomic Testing Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Lung Cancer Genomic Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Lung Cancer Genomic Testing in 2022
3.2.3 Global Concentration Ratios (CR8) for Lung Cancer Genomic Testing in 2022
3.3 Lung Cancer Genomic Testing Company Evaluation Quadrant
3.4 Lung Cancer Genomic Testing Market: Overall Company Footprint Analysis
3.4.1 Lung Cancer Genomic Testing Market: Region Footprint
3.4.2 Lung Cancer Genomic Testing Market: Company Product Type Footprint
3.4.3 Lung Cancer Genomic Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Lung Cancer Genomic Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Lung Cancer Genomic Testing Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Lung Cancer Genomic Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Lung Cancer Genomic Testing Consumption Value Comparison
4.2.1 United States VS China: Lung Cancer Genomic Testing Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Lung Cancer Genomic Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Lung Cancer Genomic Testing Companies and Market Share, 2018-2023
4.3.1 United States Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023)
4.4 China Based Companies Lung Cancer Genomic Testing Revenue and Market Share, 2018-2023
4.4.1 China Based Lung Cancer Genomic Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023)
4.5 Rest of World Based Lung Cancer Genomic Testing Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Lung Cancer Genomic Testing Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Liquid Biopsy
5.2.2 Tissue Biopsy
5.3 Market Segment by Type
5.3.1 World Lung Cancer Genomic Testing Market Size by Type (2018-2023)
5.3.2 World Lung Cancer Genomic Testing Market Size by Type (2024-2029)
5.3.3 World Lung Cancer Genomic Testing Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Lung Cancer Genomic Testing Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospitals/Clinics
6.2.2 Research Organization
6.2.3 Diagnostic Laboratories
6.3 Market Segment by Application
6.3.1 World Lung Cancer Genomic Testing Market Size by Application (2018-2023)
6.3.2 World Lung Cancer Genomic Testing Market Size by Application (2024-2029)
6.3.3 World Lung Cancer Genomic Testing Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 CD Genomics
7.1.1 CD Genomics Details
7.1.2 CD Genomics Major Business
7.1.3 CD Genomics Lung Cancer Genomic Testing Product and Services
7.1.4 CD Genomics Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 CD Genomics Recent Developments/Updates
7.1.6 CD Genomics Competitive Strengths & Weaknesses
7.2 Qiagen NV
7.2.1 Qiagen NV Details
7.2.2 Qiagen NV Major Business
7.2.3 Qiagen NV Lung Cancer Genomic Testing Product and Services
7.2.4 Qiagen NV Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Qiagen NV Recent Developments/Updates
7.2.6 Qiagen NV Competitive Strengths & Weaknesses
7.3 Laboratory Corporation of America Holdings
7.3.1 Laboratory Corporation of America Holdings Details
7.3.2 Laboratory Corporation of America Holdings Major Business
7.3.3 Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Product and Services
7.3.4 Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Laboratory Corporation of America Holdings Recent Developments/Updates
7.3.6 Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
7.4 NeoGenomics Laboratories
7.4.1 NeoGenomics Laboratories Details
7.4.2 NeoGenomics Laboratories Major Business
7.4.3 NeoGenomics Laboratories Lung Cancer Genomic Testing Product and Services
7.4.4 NeoGenomics Laboratories Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 NeoGenomics Laboratories Recent Developments/Updates
7.4.6 NeoGenomics Laboratories Competitive Strengths & Weaknesses
7.5 Agilent Technologies Inc.
7.5.1 Agilent Technologies Inc. Details
7.5.2 Agilent Technologies Inc. Major Business
7.5.3 Agilent Technologies Inc. Lung Cancer Genomic Testing Product and Services
7.5.4 Agilent Technologies Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Agilent Technologies Inc. Recent Developments/Updates
7.5.6 Agilent Technologies Inc. Competitive Strengths & Weaknesses
7.6 Illumina Inc.
7.6.1 Illumina Inc. Details
7.6.2 Illumina Inc. Major Business
7.6.3 Illumina Inc. Lung Cancer Genomic Testing Product and Services
7.6.4 Illumina Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Illumina Inc. Recent Developments/Updates
7.6.6 Illumina Inc. Competitive Strengths & Weaknesses
7.7 Thermo Fischer Scientific Inc.
7.7.1 Thermo Fischer Scientific Inc. Details
7.7.2 Thermo Fischer Scientific Inc. Major Business
7.7.3 Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Product and Services
7.7.4 Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Thermo Fischer Scientific Inc. Recent Developments/Updates
7.7.6 Thermo Fischer Scientific Inc. Competitive Strengths & Weaknesses
7.8 Abbott Laboratories Inc.
7.8.1 Abbott Laboratories Inc. Details
7.8.2 Abbott Laboratories Inc. Major Business
7.8.3 Abbott Laboratories Inc. Lung Cancer Genomic Testing Product and Services
7.8.4 Abbott Laboratories Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Abbott Laboratories Inc. Recent Developments/Updates
7.8.6 Abbott Laboratories Inc. Competitive Strengths & Weaknesses
7.9 Quest Diagnostics Inc.
7.9.1 Quest Diagnostics Inc. Details
7.9.2 Quest Diagnostics Inc. Major Business
7.9.3 Quest Diagnostics Inc. Lung Cancer Genomic Testing Product and Services
7.9.4 Quest Diagnostics Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Quest Diagnostics Inc. Recent Developments/Updates
7.9.6 Quest Diagnostics Inc. Competitive Strengths & Weaknesses
7.10 OncoDNA
7.10.1 OncoDNA Details
7.10.2 OncoDNA Major Business
7.10.3 OncoDNA Lung Cancer Genomic Testing Product and Services
7.10.4 OncoDNA Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 OncoDNA Recent Developments/Updates
7.10.6 OncoDNA Competitive Strengths & Weaknesses
7.11 Centogene N.V.
7.11.1 Centogene N.V. Details
7.11.2 Centogene N.V. Major Business
7.11.3 Centogene N.V. Lung Cancer Genomic Testing Product and Services
7.11.4 Centogene N.V. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Centogene N.V. Recent Developments/Updates
7.11.6 Centogene N.V. Competitive Strengths & Weaknesses
7.12 Admera Health
7.12.1 Admera Health Details
7.12.2 Admera Health Major Business
7.12.3 Admera Health Lung Cancer Genomic Testing Product and Services
7.12.4 Admera Health Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Admera Health Recent Developments/Updates
7.12.6 Admera Health Competitive Strengths & Weaknesses
7.13 CeGaT GmbH
7.13.1 CeGaT GmbH Details
7.13.2 CeGaT GmbH Major Business
7.13.3 CeGaT GmbH Lung Cancer Genomic Testing Product and Services
7.13.4 CeGaT GmbH Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 CeGaT GmbH Recent Developments/Updates
7.13.6 CeGaT GmbH Competitive Strengths & Weaknesses
7.14 OPKO Health Inc.
7.14.1 OPKO Health Inc. Details
7.14.2 OPKO Health Inc. Major Business
7.14.3 OPKO Health Inc. Lung Cancer Genomic Testing Product and Services
7.14.4 OPKO Health Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 OPKO Health Inc. Recent Developments/Updates
7.14.6 OPKO Health Inc. Competitive Strengths & Weaknesses
7.15 F. Hoffmann-La Roche AG.
7.15.1 F. Hoffmann-La Roche AG. Details
7.15.2 F. Hoffmann-La Roche AG. Major Business
7.15.3 F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Product and Services
7.15.4 F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 F. Hoffmann-La Roche AG. Recent Developments/Updates
7.15.6 F. Hoffmann-La Roche AG. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Lung Cancer Genomic Testing Industry Chain
8.2 Lung Cancer Genomic Testing Upstream Analysis
8.3 Lung Cancer Genomic Testing Midstream Analysis
8.4 Lung Cancer Genomic Testing Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Lung Cancer Genomic Testing Introduction
1.2 World Lung Cancer Genomic Testing Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Lung Cancer Genomic Testing Total Market by Region (by Headquarter Location)
1.3.1 World Lung Cancer Genomic Testing Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.3 China Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.4 Europe Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.5 Japan Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.6 South Korea Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.7 ASEAN Lung Cancer Genomic Testing Market Size (2018-2029)
1.3.8 India Lung Cancer Genomic Testing Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Lung Cancer Genomic Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Lung Cancer Genomic Testing Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.2 World Lung Cancer Genomic Testing Consumption Value by Region
2.2.1 World Lung Cancer Genomic Testing Consumption Value by Region (2018-2023)
2.2.2 World Lung Cancer Genomic Testing Consumption Value Forecast by Region (2024-2029)
2.3 United States Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.4 China Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.5 Europe Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.6 Japan Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.7 South Korea Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.8 ASEAN Lung Cancer Genomic Testing Consumption Value (2018-2029)
2.9 India Lung Cancer Genomic Testing Consumption Value (2018-2029)
3 WORLD LUNG CANCER GENOMIC TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Lung Cancer Genomic Testing Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Lung Cancer Genomic Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Lung Cancer Genomic Testing in 2022
3.2.3 Global Concentration Ratios (CR8) for Lung Cancer Genomic Testing in 2022
3.3 Lung Cancer Genomic Testing Company Evaluation Quadrant
3.4 Lung Cancer Genomic Testing Market: Overall Company Footprint Analysis
3.4.1 Lung Cancer Genomic Testing Market: Region Footprint
3.4.2 Lung Cancer Genomic Testing Market: Company Product Type Footprint
3.4.3 Lung Cancer Genomic Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Lung Cancer Genomic Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Lung Cancer Genomic Testing Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Lung Cancer Genomic Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Lung Cancer Genomic Testing Consumption Value Comparison
4.2.1 United States VS China: Lung Cancer Genomic Testing Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Lung Cancer Genomic Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Lung Cancer Genomic Testing Companies and Market Share, 2018-2023
4.3.1 United States Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023)
4.4 China Based Companies Lung Cancer Genomic Testing Revenue and Market Share, 2018-2023
4.4.1 China Based Lung Cancer Genomic Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023)
4.5 Rest of World Based Lung Cancer Genomic Testing Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Lung Cancer Genomic Testing Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Liquid Biopsy
5.2.2 Tissue Biopsy
5.3 Market Segment by Type
5.3.1 World Lung Cancer Genomic Testing Market Size by Type (2018-2023)
5.3.2 World Lung Cancer Genomic Testing Market Size by Type (2024-2029)
5.3.3 World Lung Cancer Genomic Testing Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Lung Cancer Genomic Testing Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospitals/Clinics
6.2.2 Research Organization
6.2.3 Diagnostic Laboratories
6.3 Market Segment by Application
6.3.1 World Lung Cancer Genomic Testing Market Size by Application (2018-2023)
6.3.2 World Lung Cancer Genomic Testing Market Size by Application (2024-2029)
6.3.3 World Lung Cancer Genomic Testing Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 CD Genomics
7.1.1 CD Genomics Details
7.1.2 CD Genomics Major Business
7.1.3 CD Genomics Lung Cancer Genomic Testing Product and Services
7.1.4 CD Genomics Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 CD Genomics Recent Developments/Updates
7.1.6 CD Genomics Competitive Strengths & Weaknesses
7.2 Qiagen NV
7.2.1 Qiagen NV Details
7.2.2 Qiagen NV Major Business
7.2.3 Qiagen NV Lung Cancer Genomic Testing Product and Services
7.2.4 Qiagen NV Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Qiagen NV Recent Developments/Updates
7.2.6 Qiagen NV Competitive Strengths & Weaknesses
7.3 Laboratory Corporation of America Holdings
7.3.1 Laboratory Corporation of America Holdings Details
7.3.2 Laboratory Corporation of America Holdings Major Business
7.3.3 Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Product and Services
7.3.4 Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Laboratory Corporation of America Holdings Recent Developments/Updates
7.3.6 Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
7.4 NeoGenomics Laboratories
7.4.1 NeoGenomics Laboratories Details
7.4.2 NeoGenomics Laboratories Major Business
7.4.3 NeoGenomics Laboratories Lung Cancer Genomic Testing Product and Services
7.4.4 NeoGenomics Laboratories Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 NeoGenomics Laboratories Recent Developments/Updates
7.4.6 NeoGenomics Laboratories Competitive Strengths & Weaknesses
7.5 Agilent Technologies Inc.
7.5.1 Agilent Technologies Inc. Details
7.5.2 Agilent Technologies Inc. Major Business
7.5.3 Agilent Technologies Inc. Lung Cancer Genomic Testing Product and Services
7.5.4 Agilent Technologies Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Agilent Technologies Inc. Recent Developments/Updates
7.5.6 Agilent Technologies Inc. Competitive Strengths & Weaknesses
7.6 Illumina Inc.
7.6.1 Illumina Inc. Details
7.6.2 Illumina Inc. Major Business
7.6.3 Illumina Inc. Lung Cancer Genomic Testing Product and Services
7.6.4 Illumina Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Illumina Inc. Recent Developments/Updates
7.6.6 Illumina Inc. Competitive Strengths & Weaknesses
7.7 Thermo Fischer Scientific Inc.
7.7.1 Thermo Fischer Scientific Inc. Details
7.7.2 Thermo Fischer Scientific Inc. Major Business
7.7.3 Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Product and Services
7.7.4 Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Thermo Fischer Scientific Inc. Recent Developments/Updates
7.7.6 Thermo Fischer Scientific Inc. Competitive Strengths & Weaknesses
7.8 Abbott Laboratories Inc.
7.8.1 Abbott Laboratories Inc. Details
7.8.2 Abbott Laboratories Inc. Major Business
7.8.3 Abbott Laboratories Inc. Lung Cancer Genomic Testing Product and Services
7.8.4 Abbott Laboratories Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Abbott Laboratories Inc. Recent Developments/Updates
7.8.6 Abbott Laboratories Inc. Competitive Strengths & Weaknesses
7.9 Quest Diagnostics Inc.
7.9.1 Quest Diagnostics Inc. Details
7.9.2 Quest Diagnostics Inc. Major Business
7.9.3 Quest Diagnostics Inc. Lung Cancer Genomic Testing Product and Services
7.9.4 Quest Diagnostics Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Quest Diagnostics Inc. Recent Developments/Updates
7.9.6 Quest Diagnostics Inc. Competitive Strengths & Weaknesses
7.10 OncoDNA
7.10.1 OncoDNA Details
7.10.2 OncoDNA Major Business
7.10.3 OncoDNA Lung Cancer Genomic Testing Product and Services
7.10.4 OncoDNA Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 OncoDNA Recent Developments/Updates
7.10.6 OncoDNA Competitive Strengths & Weaknesses
7.11 Centogene N.V.
7.11.1 Centogene N.V. Details
7.11.2 Centogene N.V. Major Business
7.11.3 Centogene N.V. Lung Cancer Genomic Testing Product and Services
7.11.4 Centogene N.V. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Centogene N.V. Recent Developments/Updates
7.11.6 Centogene N.V. Competitive Strengths & Weaknesses
7.12 Admera Health
7.12.1 Admera Health Details
7.12.2 Admera Health Major Business
7.12.3 Admera Health Lung Cancer Genomic Testing Product and Services
7.12.4 Admera Health Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Admera Health Recent Developments/Updates
7.12.6 Admera Health Competitive Strengths & Weaknesses
7.13 CeGaT GmbH
7.13.1 CeGaT GmbH Details
7.13.2 CeGaT GmbH Major Business
7.13.3 CeGaT GmbH Lung Cancer Genomic Testing Product and Services
7.13.4 CeGaT GmbH Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 CeGaT GmbH Recent Developments/Updates
7.13.6 CeGaT GmbH Competitive Strengths & Weaknesses
7.14 OPKO Health Inc.
7.14.1 OPKO Health Inc. Details
7.14.2 OPKO Health Inc. Major Business
7.14.3 OPKO Health Inc. Lung Cancer Genomic Testing Product and Services
7.14.4 OPKO Health Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 OPKO Health Inc. Recent Developments/Updates
7.14.6 OPKO Health Inc. Competitive Strengths & Weaknesses
7.15 F. Hoffmann-La Roche AG.
7.15.1 F. Hoffmann-La Roche AG. Details
7.15.2 F. Hoffmann-La Roche AG. Major Business
7.15.3 F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Product and Services
7.15.4 F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 F. Hoffmann-La Roche AG. Recent Developments/Updates
7.15.6 F. Hoffmann-La Roche AG. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Lung Cancer Genomic Testing Industry Chain
8.2 Lung Cancer Genomic Testing Upstream Analysis
8.3 Lung Cancer Genomic Testing Midstream Analysis
8.4 Lung Cancer Genomic Testing Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Lung Cancer Genomic Testing Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Lung Cancer Genomic Testing Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Lung Cancer Genomic Testing Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Lung Cancer Genomic Testing Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Lung Cancer Genomic Testing Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Lung Cancer Genomic Testing Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Lung Cancer Genomic Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Lung Cancer Genomic Testing Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Lung Cancer Genomic Testing Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Lung Cancer Genomic Testing Players in 2022
Table 12. World Lung Cancer Genomic Testing Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Lung Cancer Genomic Testing Company Evaluation Quadrant
Table 14. Head Office of Key Lung Cancer Genomic Testing Player
Table 15. Lung Cancer Genomic Testing Market: Company Product Type Footprint
Table 16. Lung Cancer Genomic Testing Market: Company Product Application Footprint
Table 17. Lung Cancer Genomic Testing Mergers & Acquisitions Activity
Table 18. United States VS China Lung Cancer Genomic Testing Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Lung Cancer Genomic Testing Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Lung Cancer Genomic Testing Revenue Market Share (2018-2023)
Table 23. China Based Lung Cancer Genomic Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Lung Cancer Genomic Testing Revenue Market Share (2018-2023)
Table 26. Rest of World Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Lung Cancer Genomic Testing Revenue Market Share (2018-2023)
Table 29. World Lung Cancer Genomic Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Lung Cancer Genomic Testing Market Size by Type (2018-2023) & (USD Million)
Table 31. World Lung Cancer Genomic Testing Market Size by Type (2024-2029) & (USD Million)
Table 32. World Lung Cancer Genomic Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Lung Cancer Genomic Testing Market Size by Application (2018-2023) & (USD Million)
Table 34. World Lung Cancer Genomic Testing Market Size by Application (2024-2029) & (USD Million)
Table 35. CD Genomics Basic Information, Area Served and Competitors
Table 36. CD Genomics Major Business
Table 37. CD Genomics Lung Cancer Genomic Testing Product and Services
Table 38. CD Genomics Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. CD Genomics Recent Developments/Updates
Table 40. CD Genomics Competitive Strengths & Weaknesses
Table 41. Qiagen NV Basic Information, Area Served and Competitors
Table 42. Qiagen NV Major Business
Table 43. Qiagen NV Lung Cancer Genomic Testing Product and Services
Table 44. Qiagen NV Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Qiagen NV Recent Developments/Updates
Table 46. Qiagen NV Competitive Strengths & Weaknesses
Table 47. Laboratory Corporation of America Holdings Basic Information, Area Served and Competitors
Table 48. Laboratory Corporation of America Holdings Major Business
Table 49. Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Product and Services
Table 50. Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Laboratory Corporation of America Holdings Recent Developments/Updates
Table 52. Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
Table 53. NeoGenomics Laboratories Basic Information, Area Served and Competitors
Table 54. NeoGenomics Laboratories Major Business
Table 55. NeoGenomics Laboratories Lung Cancer Genomic Testing Product and Services
Table 56. NeoGenomics Laboratories Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. NeoGenomics Laboratories Recent Developments/Updates
Table 58. NeoGenomics Laboratories Competitive Strengths & Weaknesses
Table 59. Agilent Technologies Inc. Basic Information, Area Served and Competitors
Table 60. Agilent Technologies Inc. Major Business
Table 61. Agilent Technologies Inc. Lung Cancer Genomic Testing Product and Services
Table 62. Agilent Technologies Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Agilent Technologies Inc. Recent Developments/Updates
Table 64. Agilent Technologies Inc. Competitive Strengths & Weaknesses
Table 65. Illumina Inc. Basic Information, Area Served and Competitors
Table 66. Illumina Inc. Major Business
Table 67. Illumina Inc. Lung Cancer Genomic Testing Product and Services
Table 68. Illumina Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Illumina Inc. Recent Developments/Updates
Table 70. Illumina Inc. Competitive Strengths & Weaknesses
Table 71. Thermo Fischer Scientific Inc. Basic Information, Area Served and Competitors
Table 72. Thermo Fischer Scientific Inc. Major Business
Table 73. Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Product and Services
Table 74. Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Thermo Fischer Scientific Inc. Recent Developments/Updates
Table 76. Thermo Fischer Scientific Inc. Competitive Strengths & Weaknesses
Table 77. Abbott Laboratories Inc. Basic Information, Area Served and Competitors
Table 78. Abbott Laboratories Inc. Major Business
Table 79. Abbott Laboratories Inc. Lung Cancer Genomic Testing Product and Services
Table 80. Abbott Laboratories Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Abbott Laboratories Inc. Recent Developments/Updates
Table 82. Abbott Laboratories Inc. Competitive Strengths & Weaknesses
Table 83. Quest Diagnostics Inc. Basic Information, Area Served and Competitors
Table 84. Quest Diagnostics Inc. Major Business
Table 85. Quest Diagnostics Inc. Lung Cancer Genomic Testing Product and Services
Table 86. Quest Diagnostics Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Quest Diagnostics Inc. Recent Developments/Updates
Table 88. Quest Diagnostics Inc. Competitive Strengths & Weaknesses
Table 89. OncoDNA Basic Information, Area Served and Competitors
Table 90. OncoDNA Major Business
Table 91. OncoDNA Lung Cancer Genomic Testing Product and Services
Table 92. OncoDNA Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. OncoDNA Recent Developments/Updates
Table 94. OncoDNA Competitive Strengths & Weaknesses
Table 95. Centogene N.V. Basic Information, Area Served and Competitors
Table 96. Centogene N.V. Major Business
Table 97. Centogene N.V. Lung Cancer Genomic Testing Product and Services
Table 98. Centogene N.V. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Centogene N.V. Recent Developments/Updates
Table 100. Centogene N.V. Competitive Strengths & Weaknesses
Table 101. Admera Health Basic Information, Area Served and Competitors
Table 102. Admera Health Major Business
Table 103. Admera Health Lung Cancer Genomic Testing Product and Services
Table 104. Admera Health Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Admera Health Recent Developments/Updates
Table 106. Admera Health Competitive Strengths & Weaknesses
Table 107. CeGaT GmbH Basic Information, Area Served and Competitors
Table 108. CeGaT GmbH Major Business
Table 109. CeGaT GmbH Lung Cancer Genomic Testing Product and Services
Table 110. CeGaT GmbH Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. CeGaT GmbH Recent Developments/Updates
Table 112. CeGaT GmbH Competitive Strengths & Weaknesses
Table 113. OPKO Health Inc. Basic Information, Area Served and Competitors
Table 114. OPKO Health Inc. Major Business
Table 115. OPKO Health Inc. Lung Cancer Genomic Testing Product and Services
Table 116. OPKO Health Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. OPKO Health Inc. Recent Developments/Updates
Table 118. F. Hoffmann-La Roche AG. Basic Information, Area Served and Competitors
Table 119. F. Hoffmann-La Roche AG. Major Business
Table 120. F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Product and Services
Table 121. F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Lung Cancer Genomic Testing Upstream (Raw Materials)
Table 123. Lung Cancer Genomic Testing Typical Customers
Table 1. World Lung Cancer Genomic Testing Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Lung Cancer Genomic Testing Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Lung Cancer Genomic Testing Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Lung Cancer Genomic Testing Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Lung Cancer Genomic Testing Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Lung Cancer Genomic Testing Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Lung Cancer Genomic Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Lung Cancer Genomic Testing Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Lung Cancer Genomic Testing Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Lung Cancer Genomic Testing Players in 2022
Table 12. World Lung Cancer Genomic Testing Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Lung Cancer Genomic Testing Company Evaluation Quadrant
Table 14. Head Office of Key Lung Cancer Genomic Testing Player
Table 15. Lung Cancer Genomic Testing Market: Company Product Type Footprint
Table 16. Lung Cancer Genomic Testing Market: Company Product Application Footprint
Table 17. Lung Cancer Genomic Testing Mergers & Acquisitions Activity
Table 18. United States VS China Lung Cancer Genomic Testing Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Lung Cancer Genomic Testing Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Lung Cancer Genomic Testing Revenue Market Share (2018-2023)
Table 23. China Based Lung Cancer Genomic Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Lung Cancer Genomic Testing Revenue Market Share (2018-2023)
Table 26. Rest of World Based Lung Cancer Genomic Testing Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Lung Cancer Genomic Testing Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Lung Cancer Genomic Testing Revenue Market Share (2018-2023)
Table 29. World Lung Cancer Genomic Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Lung Cancer Genomic Testing Market Size by Type (2018-2023) & (USD Million)
Table 31. World Lung Cancer Genomic Testing Market Size by Type (2024-2029) & (USD Million)
Table 32. World Lung Cancer Genomic Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Lung Cancer Genomic Testing Market Size by Application (2018-2023) & (USD Million)
Table 34. World Lung Cancer Genomic Testing Market Size by Application (2024-2029) & (USD Million)
Table 35. CD Genomics Basic Information, Area Served and Competitors
Table 36. CD Genomics Major Business
Table 37. CD Genomics Lung Cancer Genomic Testing Product and Services
Table 38. CD Genomics Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. CD Genomics Recent Developments/Updates
Table 40. CD Genomics Competitive Strengths & Weaknesses
Table 41. Qiagen NV Basic Information, Area Served and Competitors
Table 42. Qiagen NV Major Business
Table 43. Qiagen NV Lung Cancer Genomic Testing Product and Services
Table 44. Qiagen NV Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Qiagen NV Recent Developments/Updates
Table 46. Qiagen NV Competitive Strengths & Weaknesses
Table 47. Laboratory Corporation of America Holdings Basic Information, Area Served and Competitors
Table 48. Laboratory Corporation of America Holdings Major Business
Table 49. Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Product and Services
Table 50. Laboratory Corporation of America Holdings Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Laboratory Corporation of America Holdings Recent Developments/Updates
Table 52. Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
Table 53. NeoGenomics Laboratories Basic Information, Area Served and Competitors
Table 54. NeoGenomics Laboratories Major Business
Table 55. NeoGenomics Laboratories Lung Cancer Genomic Testing Product and Services
Table 56. NeoGenomics Laboratories Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. NeoGenomics Laboratories Recent Developments/Updates
Table 58. NeoGenomics Laboratories Competitive Strengths & Weaknesses
Table 59. Agilent Technologies Inc. Basic Information, Area Served and Competitors
Table 60. Agilent Technologies Inc. Major Business
Table 61. Agilent Technologies Inc. Lung Cancer Genomic Testing Product and Services
Table 62. Agilent Technologies Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Agilent Technologies Inc. Recent Developments/Updates
Table 64. Agilent Technologies Inc. Competitive Strengths & Weaknesses
Table 65. Illumina Inc. Basic Information, Area Served and Competitors
Table 66. Illumina Inc. Major Business
Table 67. Illumina Inc. Lung Cancer Genomic Testing Product and Services
Table 68. Illumina Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Illumina Inc. Recent Developments/Updates
Table 70. Illumina Inc. Competitive Strengths & Weaknesses
Table 71. Thermo Fischer Scientific Inc. Basic Information, Area Served and Competitors
Table 72. Thermo Fischer Scientific Inc. Major Business
Table 73. Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Product and Services
Table 74. Thermo Fischer Scientific Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Thermo Fischer Scientific Inc. Recent Developments/Updates
Table 76. Thermo Fischer Scientific Inc. Competitive Strengths & Weaknesses
Table 77. Abbott Laboratories Inc. Basic Information, Area Served and Competitors
Table 78. Abbott Laboratories Inc. Major Business
Table 79. Abbott Laboratories Inc. Lung Cancer Genomic Testing Product and Services
Table 80. Abbott Laboratories Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Abbott Laboratories Inc. Recent Developments/Updates
Table 82. Abbott Laboratories Inc. Competitive Strengths & Weaknesses
Table 83. Quest Diagnostics Inc. Basic Information, Area Served and Competitors
Table 84. Quest Diagnostics Inc. Major Business
Table 85. Quest Diagnostics Inc. Lung Cancer Genomic Testing Product and Services
Table 86. Quest Diagnostics Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Quest Diagnostics Inc. Recent Developments/Updates
Table 88. Quest Diagnostics Inc. Competitive Strengths & Weaknesses
Table 89. OncoDNA Basic Information, Area Served and Competitors
Table 90. OncoDNA Major Business
Table 91. OncoDNA Lung Cancer Genomic Testing Product and Services
Table 92. OncoDNA Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. OncoDNA Recent Developments/Updates
Table 94. OncoDNA Competitive Strengths & Weaknesses
Table 95. Centogene N.V. Basic Information, Area Served and Competitors
Table 96. Centogene N.V. Major Business
Table 97. Centogene N.V. Lung Cancer Genomic Testing Product and Services
Table 98. Centogene N.V. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Centogene N.V. Recent Developments/Updates
Table 100. Centogene N.V. Competitive Strengths & Weaknesses
Table 101. Admera Health Basic Information, Area Served and Competitors
Table 102. Admera Health Major Business
Table 103. Admera Health Lung Cancer Genomic Testing Product and Services
Table 104. Admera Health Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Admera Health Recent Developments/Updates
Table 106. Admera Health Competitive Strengths & Weaknesses
Table 107. CeGaT GmbH Basic Information, Area Served and Competitors
Table 108. CeGaT GmbH Major Business
Table 109. CeGaT GmbH Lung Cancer Genomic Testing Product and Services
Table 110. CeGaT GmbH Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. CeGaT GmbH Recent Developments/Updates
Table 112. CeGaT GmbH Competitive Strengths & Weaknesses
Table 113. OPKO Health Inc. Basic Information, Area Served and Competitors
Table 114. OPKO Health Inc. Major Business
Table 115. OPKO Health Inc. Lung Cancer Genomic Testing Product and Services
Table 116. OPKO Health Inc. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. OPKO Health Inc. Recent Developments/Updates
Table 118. F. Hoffmann-La Roche AG. Basic Information, Area Served and Competitors
Table 119. F. Hoffmann-La Roche AG. Major Business
Table 120. F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Product and Services
Table 121. F. Hoffmann-La Roche AG. Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Lung Cancer Genomic Testing Upstream (Raw Materials)
Table 123. Lung Cancer Genomic Testing Typical Customers
LIST OF FIGURES
Figure 1. Lung Cancer Genomic Testing Picture
Figure 2. World Lung Cancer Genomic Testing Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Lung Cancer Genomic Testing Total Market Size (2018-2029) & (USD Million)
Figure 4. World Lung Cancer Genomic Testing Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Lung Cancer Genomic Testing Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 13. Lung Cancer Genomic Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 16. World Lung Cancer Genomic Testing Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 18. China Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 23. India Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Lung Cancer Genomic Testing by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Lung Cancer Genomic Testing Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Lung Cancer Genomic Testing Markets in 2022
Figure 27. United States VS China: Lung Cancer Genomic Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Lung Cancer Genomic Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Lung Cancer Genomic Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Lung Cancer Genomic Testing Market Size Market Share by Type in 2022
Figure 31. Liquid Biopsy
Figure 32. Tissue Biopsy
Figure 33. World Lung Cancer Genomic Testing Market Size Market Share by Type (2018-2029)
Figure 34. World Lung Cancer Genomic Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Lung Cancer Genomic Testing Market Size Market Share by Application in 2022
Figure 36. Hospitals/Clinics
Figure 37. Research Organization
Figure 38. Diagnostic Laboratories
Figure 39. Lung Cancer Genomic Testing Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
Figure 1. Lung Cancer Genomic Testing Picture
Figure 2. World Lung Cancer Genomic Testing Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Lung Cancer Genomic Testing Total Market Size (2018-2029) & (USD Million)
Figure 4. World Lung Cancer Genomic Testing Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Lung Cancer Genomic Testing Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Lung Cancer Genomic Testing Revenue (2018-2029) & (USD Million)
Figure 13. Lung Cancer Genomic Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 16. World Lung Cancer Genomic Testing Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 18. China Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 23. India Lung Cancer Genomic Testing Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Lung Cancer Genomic Testing by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Lung Cancer Genomic Testing Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Lung Cancer Genomic Testing Markets in 2022
Figure 27. United States VS China: Lung Cancer Genomic Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Lung Cancer Genomic Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Lung Cancer Genomic Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Lung Cancer Genomic Testing Market Size Market Share by Type in 2022
Figure 31. Liquid Biopsy
Figure 32. Tissue Biopsy
Figure 33. World Lung Cancer Genomic Testing Market Size Market Share by Type (2018-2029)
Figure 34. World Lung Cancer Genomic Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Lung Cancer Genomic Testing Market Size Market Share by Application in 2022
Figure 36. Hospitals/Clinics
Figure 37. Research Organization
Figure 38. Diagnostic Laboratories
Figure 39. Lung Cancer Genomic Testing Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
